SCHEMBL5536166

SCHEMBL5536166

Cc1cc2nccc([O])c2cc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.41
EGFR P00533 2/20 0.37
CSF1R P07333 2/20 0.37
SRC P12931 1/20 0.36
TGFBR1 P36897 1/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 1/20 0.36
HTR1A P08908 3/20 0.36
ADRA1D P25100 3/20 0.36
ADRA1A P35348 3/20 0.36
ADRA1B P35368 3/20 0.36
NQO2 P16083 1/20 0.35
CCR1 P32246 1/20 0.35
CCR5 P51681 1/20 0.35
CCR8 P51685 1/20 0.35
TLR8 Q9NR97 2/20 0.35
MEN1 O00255 1/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL862238 0.80 CCR1 (0.50) ATAD2EGFRCSF1RKDM4ENPC1
SCHEMBL11758378 0.79 CCR1 (0.50) ATAD2SRCTGFBR1KDM4ENPC1
SCHEMBL5539375 0.78 HTR1A (0.54) KDM4ENPC1HTR1AADRA1DADRA1A
SCHEMBL5543680 0.78 HTR1A (0.54) SRCTGFBR1KDM4ENPC1HTR1A
SCHEMBL15960727 0.75 TLR8 (0.45) ATAD2EGFRCSF1RSRCTGFBR1
SCHEMBL6002911 0.75 TLR8 (0.43) SRCKDM4ENPC1HTR1AADRA1D
SCHEMBL27518763 0.75 PDGFRB (0.55) EGFRSRCTGFBR1
SCHEMBL14289086 0.72 SMN1; SMN2 (0.36) ATAD2EGFRCSF1RSRCTGFBR1
SCHEMBL26237873 0.72 GPR55 (0.38) ATAD2EGFRCSF1RSRCTGFBR1
SCHEMBL29287971 0.69 PIK3CA (0.55) CSF1RKDM4ENPC1NQO2TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ATAD2 1255/4885EGFR 3049/4885CSF1R 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.